{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-090727","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.058955+00:00","generated_at":"2026-05-31T13:08:49.146310+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CRISPR Therapeutics Q2 2024 net loss widens to $126.4M; CASGEVY launch with 35+ ATCs","bullets":["Net loss $126.4M vs $77.7M in Q2 2023; R&D expenses down to $80.2M from $101.6M.","Cash, equivalents and securities $2.01B as of June 30, up from $1.70B at Dec 31, 2023.","CASGEVY: >35 ATCs activated globally; ~20 patients have had cells collected as of mid-July.","CTX112 CD19 CAR T Phase 1/2 trial opened for SLE; preliminary oncology data expected this year.","Appointed Naimish Patel as CMO; promoted Julianne Bruno to COO and Susan Kim to SVP IR."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-090727","json":"https://secwatch.observer/filing/0000950170-24-090727.json","markdown":"https://secwatch.observer/filing/0000950170-24-090727.md","text":"https://secwatch.observer/filing/0000950170-24-090727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017024090727/0000950170-24-090727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017024090727/crsp-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:08:49.146310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}